MB-107 / Fortress - LARVOL DELTA

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire) - "Mustang Bio, Inc...today announced that, on July 28, 2023, it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc....closed the transaction under the terms of the amended asset purchase agreement...Per the terms of the amended agreement, at closing, uBriGene acquired all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies for upfront consideration of $6 million in cash....At closing, Mustang and uBriGene also entered into a manufacturing services agreement, under which Mustang contracted uBriGene to manufacture Mustang’s lead product candidates. This includes the manufacturing of MB-106..."

Licensing / partnership • M&A • Brain Cancer • Chronic Lymphocytic Leukemia • CNS Tumor • Glioblastoma • Glioma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

[VIRTUAL] MBP107 - Rapid Fire: MBP (WMF 2021) - "Speakers will be present during the entirety of the session to answer questions in the Live Chat box during the presentations. This session will be recorded and available for on-demand viewing through July 30, 2021."

"$MBIO Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency" (@BioStocks)

Clinical • Genetic Disorders • Immunology • Pediatrics • Primary Immunodeficiency

"$MBIO Receives Advanced Therapy Medicinal Product Classification from the EMA for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency" (@BioStocks)

Gene Therapies • Genetic Disorders • Immunology • Primary Immunodeficiency

Fortress Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights (GlobeNewswire, Fortress Biotech, Inc.) - "In May 2019, the FDA granted Orphan Drug Designation to MB-108 (oncolytic virus C134) for the treatment of malignant glioma, a type of brain cancer with a median survival of less than 18 months."

Regulatory